The effects of (-)- and (+)-beta-cyclazocine on NMDA-evoked responses and NMDA-mediated cell damage in cultured rat hippocampal neurons.

Microspectrofluorimetric measurements of excitatory amino acid-evoked rises in intracellular free calcium concentration ([Ca2+]i), electrophysiological measurements of currents through single NMDA receptor-operated ion channels and estimates of cellular viability following NMDA challenge were employed to examine the interactions of (-)- and (+)-beta-cyclazocine with the NMDA receptor-channel complex in cultured rat hippocampal neurons. Rises in [Ca2+]i evoked by NMDA, but not those evoked by kainate, AMPA or 50 mM K+, were reduced by (-)-beta-cyclazocine in a concentration- and use-dependent manner with an estimated IC50 value of 272 nM. In outside-out patches, (-)-beta-cyclazocine did not change the magnitudes of unitary NMDA-evoked currents but diminished both the frequency of channel openings and their mean open time. The IC50 for (-)-beta-cyclazocine against NMDA channel open state probability was estimated at 84 nM. The actions of (-)-beta-cyclazocine were consistent with a voltage-dependent open channel block of the NMDA channel with a blocking rate constant of 7.03.10(7) M-1.s-1 at -40 mV. Neurons exposed to a high concentration of NMDA in vitro were protected from death by 1 and 10 microM (-)-beta-cyclazocine. In all of the above assays, (+)-beta-cyclazocine was considerably less potent an NMDA antagonist and neuroprotective agent than (-)-beta-cyclazocine; the IC50 for (+)-beta-cyclazocine against channel open state probability was estimated at 14 microM. The results demonstrate that (-)-beta-cyclazocine is a potent and selective inhibitor of NMDA-evoked responses in cultured rat hippocampal neurons and an effective neuroprotective agent in vitro.

(-)-beta-cyclazocine is an antagonist of NMDA receptor-mediated responses and a potent neuroprotectant in rat cortical neurons.

Microspectrofluorimetry and excitotoxicity experiments were performed to study the NMDA receptor-blocking and neuroprotective actions of (-)- and (+)-beta-cyclazocine in cultured rat cortical neurons. (-)-beta-Cyclazocine potently antagonized NMDA-induced[Ca2+]i increases (IC50 = 220 nM) in neurons loaded with the Ca2+ fluorophore, fura-2. (-)-beta-Cyclazocine was specific for NMDA receptor-mediated responses versus those mediated through non-NMDA receptors or voltage-activated Ca2+ channels. The agent was active against NMDA-induced neurotoxicity, even at 1 microM. In all experiments, the (+)-enantiomer was found to be considerably less potent than the (-)-enantiomer. These results indicate that (-)-beta-cyclazocine is a specific NMDA receptor antagonist with potent neuroprotective properties in rat cortical neurons.

Kappa antinociceptive activity of spiradoline in the cold-water tail-flick assay in rats.

Spiradoline (U62066E) a racemic mixture of the two enantiomers U63639(+) and U63640(-), appears to have kappa opioid receptor activity, but the contribution of each enantiomer toward this activity is still in question. To determine the activity of each enantiomer in comparison to the racemic mixture, the three forms were tested in the cold-water tail-flick (CWTF) assay in male Sprague-Dawley rats. Antinociception by spiradoline was completely antagonized by naloxone 0.50 mg/kg, a dose five times that required to antagonize antinociception by fentanyl in this same assay. In a second series of tests, fentanyl-induced antinociception was markedly reduced, while spiradoline-induced antinociception was essentially unchanged. in methadone-tolerant animals. Of the enantiomers, only U63640 produced antinociception, whereas U63639 failed to affect the nociceptive response. Additionally, spiradoline failed to produce antinociception in animals pretreated with norbinaltorphimine (kappa receptor specific), but antinociception was not affected in animals pretreated with beta-funaltrexamine (mu receptor specific). These results show that spiradoline is a full antinociceptive agonist in the CWTF assay and that the effects of the drug are mediated through kappa opioid receptors.

Oxymorphone-induced analgesia and colonic motility measured in colorectal distension.

Changes in colonic motility in rats following intravenous (IV) oxymorphone (0.1 mg/kg), atropine (0.1 mg/kg), or saline were monitored to determine whether opioid-induced changes in colonic motility affect antinociceptive measurements when using colorectal distension (CRD) as a nociceptive assay. Polygraph recordings of colonic pressures, contraction frequencies, and the pressure-volume relationship of the stimulus showed that oxymorphone produced a transient increase in contraction frequencies when compared to atropine- and saline-treated rats. The transient increase in contraction frequency caused by oxymorphone declined to baseline levels at 30 min after administration, the time at which the nociceptive threshold for CRD was tested. Neither oxymorphone nor atropine changed baseline pressures or the pressure-volume curve for the balloon stimulus. Antinociceptive results from CRD at 30 min posttreatment showed that only oxymorphone produced significant antinociception. We conclude that oxymorphone does not produce changes in colonic motility that complicate antinociceptive measurements in CRD and that CRD is an effective means of testing opioid-induced visceral antinociception.

Cardiopulmonary effects of rebreathing and nonrebreathing systems during halothane anesthesia in the cat.

Cardiopulmonary variables were measured in 3 groups of halothane-oxygen anesthetized cats. The groups, each containing 6 animals, were treated similarly except for maintenance anesthetic systems, and system variation was the basis for comparison. Groups were maintained, using a pediatric circle CO2 absorption system with an O2 flow of 0.5 L/minute, an Ayre's T-piece system with an O2 flow of 3 L/minute, and an adult circle CO2 absorption system with an O2 flow of 0.5 L/minute. Anesthesia was induced by mask, endotracheal intubation was done, and end-expired halothane was maintained at 1.4%. Measurements of cardiopulmonary variables were reported at 30-minute intervals for 135 minutes, the first measurements being made 15 minutes after induction. Control data were similar for all groups. Measured variables were not statistically or clinically different among groups, and change from control within groups was related to halothane anesthesia. The 3 systems produced similar cardiovascular and respiratory effects. Consequently, none of the systems proved superior to the other 2 on the basis of measured variables. Halothane anesthesia produced cardiopulmonary changes comparable to changes reported in other species anesthetized and maintained by similar techniques.

Electroretinography of acute hypoxic and increased intraocular pressure status in the dog.

A model for studying electroretinographic (ERG) responses during controlled hypoxia and acutely increased intraocular pressure (IOP) in dogs is described. The b-wave component of the ERG was critically affected before the a-wave. The critical perfusion pressure (PP) was 45 mm of Hg less than mean arterial blood pressure, and the dog will demonstrate altered b-wave amplitudes at hypoxic values of arterial oxygen pressure (Pao2) 0f 45 torr.

Comparison of isoflurane with sevoflurane for anesthesia induction and recovery in adult dogs.

OBJECTIVE: To compare mask anesthesia induction and recovery characteristics between 2 inhalant anesthetic agents: isoflurane and sevoflurane. ANIMALS: 16 clinically normal, young adult Beagles. PROCEDURE: Using a cross-over design, dogs were randomly selected to receive sevoflurane or isoflurane via a face mask and a circle anesthetic system. Vaporizer setting concentrations were increased in stepwise, equal minimum alveolar concentrations (MAC) for each anesthetic until the vaporizer setting of 2.6% for isoflurane or 4.8% for sevoflurane (2 MAC) was reached. Concentration was kept constant until the dog had a negative tail clamp response and was intubated. End-tidal concentration was maintained at 1.8 to 2.0% or 3.3 to 3.8% for isoflurane or sevoflurane, respectively (1.4 to 1.6 MAC) for 30 minutes. Dogs were allowed to recover with only tail clamp stimulation until a positive response was obtained. Extubation was performed when a spontaneous swallow reflex was observed. Dogs were allowed to achieve sternal recumbency and stand unassisted without further stimulation. RESULTS: Sevoflurane induction resulted in shorter time to loss of palpebral reflex, negative tail clamp response, and time to tracheal intubation, and was of better quality than isoflurane induction. Both anesthetics were associated with rapid and smooth recovery. CONCLUSIONS: Sevoflurane mask induction is faster and of better quality, compared with isoflurane, in adult dogs. Recovery time and quality are comparable. CLINICAL RELEVANCE: On the basis of these results, sevoflurane is a suitable inhalant anesthetic for mask induction and recovery in adult dogs and appears to have some advantages over isoflurane, including faster and smoother mask induction.

Cardiopulmonary effects of fentanyl-droperidol, nitrous oxide, and atropine sulfate in dogs.

The cardiopulmonary effects of droperidol-fentanyl, nitrous oxide, and atropine were evaluated in 12 adult male Beagle dogs. All dogs were surgically instrumented with a cardiac output thermistor and arterial and venous catheters and were prepared with a chronic tracheostomy. Each dog was used as its own control, and data obtained when dogs were nonanesthetized and nonmedicated were compared with data recorded after the test drugs were administered. The dogs were randomly allotted to 3 groups of 4 dogs each. Group I dogs were given droperidol-fentanyl alone intravenously (IV); group II dogs were given droperidol-fentanyl IV with 67% nitrous oxide; and group III dogs were given atropine sulfate intramuscularly followed by droperidol-fentanyl IV with 67% nitrous oxide. Minute volume was decreased in the 3 groups of dogs for 3 to 5 minutes after droperidol-fentanyl was injected. This resulted in respiratory and metabolic acidosis in all dogs, as indicated by increased arterial carbon dioxide tension, decreased pH, and increased base deficit. In addition, droperidol-fentanyl given alone caused a decrease in systolic pressure and a slight decrease in heart rate. Group 1 dogs were sensitive to auditory stimulation. Cardiovascular changes were not seen when nitrous oxide was added; however, analgesia and muscle relaxation were improved. Premedication with atropine sulfate resulted in increased cardiac output, heart rate, and diastolic pressure, and subsequent administration of droperidol-fentanyl with nitrous oxide caused a transient increase in mean arterial and systolic pressure. This last anesthetic regimen, along with assisted or controlled respiration, seems to provide an excellent anesthetic state with minimal cardiopulmonary depression.

Cardiovascular effects of gallamine triethiodide and succinylcholine chloride during halothane anesthesia in the dog.

The cardiovascular effects of gallamine triethiodide and succinylcholine chloride were studied in Beagle dogs during controlled halothane anesthesia. Small but significant increases in heart rate and mean arterial presssure were observed 1 minute after intravenous injection of succinylcholine chloride. Intravenous injection of gallamine triethiodide did not produce significant cardiovascular changes.

Analgesia and behavioral responses of dogs given oxymorphone-acepromazine and meperidine-acepromazine after methoxyflurane and halothane anesthesia.

This study was designed to test analgesia, duration, and cardiovascular changes induced by meperidine (MEP) and oxymorphone (OXY) following methoxyflurane (MOF) and halothane (HAL) anesthesia. Eight healthy dogs were given atropine and acepromazine, and anesthesia was induced with thiamylal and maintained with 1.5 minimal alveolar concentration of MOF or HAL for 1 hour during controlled ventilation. Eight treatments were given with each anesthetic: 3 with MEP (0.5, 1.0, and 2.0 mg/kg, IV), 3 with oxymorphone (OXY; 0.05, 0.1, and 0.2 mg/kg, IV), and 2 placebos with sterile water. Test drugs were given at the end of anesthesia when early signs of recovery were evident. Minimal threshold stimulus/response nociception was assessed by use of an inflatable soft plastic colonic balloon. Blood pressures and pulse rate were measured with a noninvasive monitor. Meperidine and OXY were found to be effective analgesics and could be reversed with naloxone. Intravenous administration of 2.0 mg of MEP/kg provided analgesia for 36 +/- 6 minutes and 39 +/- 15 minutes after MOF and HAL, respectively. In contrast, OXY was effective at all 3 doses with effects of IV administration of 0.2 mg of OXY/kg lasting 154 +/- 13 minutes and 152 +/- 12 minutes, after MOF and HAL, respectively. Analgesia could not be demonstrated after anesthesia for acepromazine, MOF, or HAL. Blood pressure was not changed by either anesthetic nor was it influenced by MEP or OXY. Pulse rate was significantly depressed by the higher doses of OXY following HAL, but was not changed by MEP following either anesthetic.(ABSTRACT TRUNCATED AT 250 WORDS)

Dose response to butorphanol administered subcutaneously to increase visceral nociceptive threshold in dogs.

Butorphanol (0.025, 0.05, 0.1, 0.2, 0.4, and 0.8 mg/kg of body weight, and placebo) was given SC to 8 healthy unmedicated dogs to determine its efficacy for visceral analgesia, using a colonic balloon for minimal threshold nociceptor stimulation. Degree of sedation; systolic, diastolic, and mean arterial pressure; and pulse rate were recorded. The highest 3 dosages, 0.2, 0.4, and 0.8 mg/kg, were found to be most effective, with 0.8 mg/kg the only dosage that was significantly different from control responses at the 45-minute interval. Duration of analgesia ranged from 23 to 53 minutes for all 6 dosages and dosing durations were not significantly different from one another. Blood pressures did not change, but pulse rate was significantly decreased by 0.8 mg of butorphanol/kg. We concluded that butorphanol is an effective visceral analgesic of relatively short duration in the dog.

Suffering and euthanasia.

Suffering is a powerful but elusive concept in veterinary medicine. Because the companion animal cannot talk, assessment of suffering requires the best judgment of veterinarian, family, and other interested participants. Determining whether euthanasia is appropriate rests on a similar consensus but is based on the entire medical and social situation. Clinicians need skill, sensitivity, and a well-developed sense of timing to uncover what clients really feel and want. Offering the family options, such as to be present during the euthanasia, makes the veterinarian's task easier and helps clients cope.

Local vasoactivity of oxygen and carbon dioxide in the right coronary circulation of the dog and pig.

1. Eight mongrel dogs were anaesthetized with sodium thiamylal and chloralose-urethane, ventilated, vagotomized and heparinized. Five Poland-China pigs were anaesthetized with sodium thiamylal and nitrous oxide, ventilated, vagotomized and heparinized. 2. Extracorporeal perfusion of the right coronary artery at constant pressure (100 mmHg) was instituted. A lung from a donor animal was interposed in the coronary perfusion circuit to effect changes in CO2 and O2 tensions in the coronary arterial blood while systemic blood gases were maintained at normal levels. 3. Local hypoxia (PO2 range 17-22 mmHg) produced a 25-75% decrease in coronary vascular resistance (P less than 0.05) and a 0-24% (not significant) decrease in right ventricular dP/dt. 4. Local changes in PCO2 over the range 8-105 mmHg were associated with a 17-58% decrease in coronary vascular resistance (P less than 0.05), a 19-24% decrease in right ventricular dP/dt (P less than 0.05) with no change in right ventricular end-diastolic pressure, and a 1-18% (not significant) decrease in heart rate. 5. These studies suggest that local decreases in O2 or increases in CO2 tensions produce decreases in right coronary vascular resistance that are in the opposite direction to those that would be expected from the observed changes in heart rate and contractility (two primary determinants of myocardial oxygen consumption). 6. These data support the hypothesis that CO2 and O2 are locally vasoactive in the coronary circulation.